Lytix Biopharma announces the appointment of Torbjørn Furuseth as CFO
Lytix Biopharma announces the appointment of Torbjørn Furuseth as the company’s Chief Financial Officer (CFO) from 1st of February 2017.
Before joining Lytix Biopharma, Torbjørn held the position as Executive Vice President Innovation in Aker Biomarine. Prior to Aker Biomarine Torbjørn worked as Vice President Commercial Development at Trygg Pharma and has six years of experience as management consultant at McKinsey & Co serving clients within their Pharma and Health Care practice. Torbjørn is a Medical Doctor from the Norwegian University of Science and Technology (NTNU) and has also studied biotech entrepreneurship at the Norwegian School of Entrepreneurship in San Francisco, USA.
The current CFO, Kjetil Vangsnes, will transfer to Lytix Biopharma’s sister company Amicoat AS after a short transition and handover period.
Håkan Wickholm, CEO of Lytix Biopharma says:
‘’It is with great pleasure we welcome Torbjørn Furuseth as the new CFO of Lytix Biopharma. His expertise and operational experience from various roles in the life science industry will be important as we approach essential milestones for the company.’’
‘’Also, I would like to express my gratitude to Kjetil and thank him for his great work and contributions during 2016. We wish him all the best in his role as CFO in Amicoat’’.